Regulus Therapeutics’ (RGLS) “Hold” Rating Reaffirmed at Needham & Company LLC
“Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it.”,” Needham & Company LLC’s analyst wrote.
Several other equities research analysts have also weighed in on the stock. Zacks Investment Research raised shares of Regulus Therapeutics from a hold rating to a buy rating and set a $1.50 target price on the stock in a report on Tuesday, October 10th. Wedbush reissued an ourperform rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, August 7th. Finally, Chardan Capital lowered shares of Regulus Therapeutics from a buy rating to a neutral rating in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Regulus Therapeutics presently has an average rating of Hold and a consensus target price of $2.60.
Regulus Therapeutics (RGLS) traded down $0.02 on Tuesday, hitting $0.92. 3,410,232 shares of the stock traded hands, compared to its average volume of 887,570. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. Regulus Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $3.10.
A number of large investors have recently modified their holdings of RGLS. Quantitative Investment Management LLC bought a new stake in Regulus Therapeutics during the 2nd quarter worth about $103,000. GSA Capital Partners LLP acquired a new position in Regulus Therapeutics during the 2nd quarter valued at about $139,000. LMR Partners LLP acquired a new position in Regulus Therapeutics during the 2nd quarter valued at about $164,000. Tudor Investment Corp ET AL lifted its position in Regulus Therapeutics by 131.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 61,373 shares during the period. Finally, Royal Bank of Canada lifted its position in Regulus Therapeutics by 12.1% during the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the period. 33.45% of the stock is currently owned by hedge funds and other institutional investors.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.